The combination of reduced CSF Aβ42 (or the Aβ42/Aβ40 ratio) and elevated CSF phosphorylated tau (p–tau) currently provides the most reliable in vivo proxy for AD pathology, approximating neuropathological confirmation during life (64). Here, MAPT is linked to Alzheimer disease.